Stifel upgraded Tandem Diabetes to Buy from Hold with a $37 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $31 from $25 at Citi
- Tandem Diabetes announces private placement of $250M in convertible senior notes
- Tandem Diabetes (NASDAQ:TNDM): Investors Look to Innovation to Drive the Stock Higher
- Tandem Diabetes sees Q1 revenue $175M, consensus $186.09M
- Tandem Diabetes sees FY24 non-GAAP revenue roughly $850M, consensus $842.49M